December 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Onco Therapy Science, Institute for Antibodies Conclude Licensing Agreement for Anticancer Antibody
 

Tokyo, Apr 4, 2005 (JCN) - Onco Therapy Science (OTS) announced on March 31 that the company has entered into a licensing agreement with the Institute for Antibodies (IFA), a Nagoya-based company engaged in researching and developing antigens and antibodies.

Under the terms of the agreement, OTS will exclusively develop, manufacture and distribute IFA's proprietary antibody used in the cancer treatment throughout the world.

The antibody, which this agreement encopmpasses, targets a gene used in a promising drug for small cell lung cancer. It is also expected to demonstrate superior antitumor effects on other cancers.

OTS will begin preparing for clinical trials and make every effort to pave the way for early commercialization.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  OncoTherapy Science, Inc. News  
  OncoTherapy Science, Fuso Pharmaceutical Industries Jointly Undertake Phase I Clinical Trial of Anglogenesis Inhibitor OTS102  (Mar 31, 2006)
  OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer  (Feb 1, 2006)
  OncoTherapy Science, BioWa to Collaborate in Antibody Drug Development  (Oct 25, 2005)
  Medical & Biological Laboratories to Start Clinical Trials of Two Different ELISA Reagents for Serological Diagnosis  (June 27, 2005)
  OncoTherapy Science to Start Clinical Trials of OTS102 Angiogenesis Inhibitor  (Apr 5, 2005)
  Onco Therapy Science, Institute for Antibodies Conclude Licensing Agreement for Anticancer Antibody  (Apr 4, 2005)
  OncoTherapy Science (OTS), BioWa to Join Hands in Antibody Drug Development  (Aug 10, 2004)
  MBL, OncoTherapy Science to Establish Joint Venture for Antibody Drug Business  (Aug 4, 2004)


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)